Concepción IR, Soriano GJL, Batista AN, Lima PM, Morales MD, Fleites CV

Language: Spanish
References: 0
Page:
PDF size: 159.78 Kb.

ABSTRACT

Introduction: Bone metastases from cancer affect the health related quality of life (HRQL), but it benefits with zoledronic acid.
Methods: Were evaluated 307 patients diagnosed with bone metastases from breast cancer (2011-2013), age 18-80 years, ECOG ?3, expectancy >6 months, normal function of bone marrow/ organs, patients' follow-up for 12 months. Zoledronic acid administered each 21/28 days was the treatment used in this patients, and EORTC QLQ - BM22 module assessed HRQL.
Results: Were observed more patients aged ?50 years (69 %), postmenopausal in 62.21 %, the ductal carcinoma hormonsensitive 79.15 %.Although mixed osseous lesionspresented in 65.4 %, <3 osseous sites in 86.9 %, and metastases in vertebras 57 %, skeletal related events were infrequent. At 12 months, zoledronic acid achieved better HRQL as were observed significant reduction in pain relating scales and psychosocial aspects, but non-in the functional interference.
Conclusions: Zoledronic acid treatment benefits HRQL in patients with bone metastases from breast cancer.